NASDAQ:STEX Biosig Technologies (STEX) Stock Price, News & Analysis $0.98 0.00 (-0.30%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$0.99 +0.01 (+0.98%) As of 06/9/2026 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Biosig Technologies Stock (NASDAQ:STEX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Biosig Technologies alerts:Sign Up Key Stats Today's Range$0.91▼$1.0150-Day Range$0.77▼$1.5152-Week Range$0.70▼$14.11Volume1.57 million shsAverage Volume1.74 million shsMarket Capitalization$178.60 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingHold Company Overview Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions. Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion. The technology is intended to integrate with existing electrophysiology lab equipment and workflows, supporting procedures such as ablations used to treat atrial fibrillation and other arrhythmias. By enhancing signal fidelity, the company aims to support procedural efficiency and clinical decision-making for electrophysiologists and hospital electrophysiology labs. Biosig positions its product development around clinical validation and regulatory pathways common to medical device commercialization, and it targets adoption by hospitals, specialty clinics and physician groups that perform invasive cardiac electrophysiology procedures. The company pursues clinical studies and collaborations to demonstrate the clinical utility of its technology and to support broader commercialization within the medical community. AI Generated. May Contain Errors. Read More Biosig Technologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreSTEX MarketRank™: Biosig Technologies scored higher than 52% of companies evaluated by MarketBeat, and ranked 47th out of 88 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingBiosig Technologies has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialBiosig Technologies has a consensus price target of $8.00, representing about 714.3% upside from its current price of $0.98.Amount of Analyst CoverageBiosig Technologies has only been the subject of 2 research reports in the past 90 days.Read more about Biosig Technologies' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Biosig Technologies is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biosig Technologies is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiosig Technologies has a P/B Ratio of 1.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.05% of the float of Biosig Technologies has been sold short.Short Interest Ratio / Days to CoverBiosig Technologies has a short interest ratio ("days to cover") of 2.98, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biosig Technologies has recently increased by 5.07%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiosig Technologies does not currently pay a dividend.Dividend GrowthBiosig Technologies does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.29 News SentimentBiosig Technologies has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.98 average news sentiment score of Manufacturing companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Biosig Technologies this week, compared to 2 articles on an average week.Search Interest8 people have searched for STEX on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows8 people have added Biosig Technologies to their MarketBeat watchlist in the last 30 days. Company Ownership2.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Biosig Technologies insiders have sold 45.25% more of their company's stock than they have bought. Specifically, they have bought $202,860.00 in company stock and sold $294,660.00 in company stock.Percentage Held by Insiders52.73% of the stock of Biosig Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions7.16% of the stock of Biosig Technologies is held by institutions.Read more about Biosig Technologies' insider trading history. Receive STEX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biosig Technologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STEX Stock News HeadlinesBiosig Technologies (NASDAQ:STEX) CIO Mitchell Young Williams Sells 23,810 SharesJune 3, 2026 | insidertrades.comInsider Buying: Biosig Technologies (NASDAQ:STEX) Chairman Buys 34,000 Shares of StockMay 29, 2026 | insidertrades.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift. | Porter & Company (Ad)Streamex Corp. and Orca Announce Launch of 24/7 Decentralized Secondary Liquidity Infrastructure for Tokenized Securities; GLDY the Inaugural AssetMay 27, 2026 | globenewswire.comStreamex Corp. Appoints Former Microsoft and PayPal Lead Product Designer Kori Handy as Vice President of Product and DesignMay 26, 2026 | globenewswire.comInsider Buying: Biosig Technologies (NASDAQ:STEX) Chairman Purchases 147,000 Shares of StockMay 22, 2026 | insidertrades.comStreamex Corp. Provides Q1 2026 Earnings and Corporate Update Presentation Recap; Highlights New Partnerships & Key UpdatesMay 21, 2026 | globenewswire.comStreamex Corp. Announces April 2026 Yield Dividend Distribution for GLDYMay 18, 2026 | globenewswire.comSee More Headlines STEX Stock Analysis - Frequently Asked Questions How have STEX shares performed this year? Biosig Technologies' stock was trading at $3.40 at the beginning of 2026. Since then, STEX shares have decreased by 71.1% and is now trading at $0.9824. How were Biosig Technologies' earnings last quarter? Biosig Technologies, Inc. (NASDAQ:STEX) posted its quarterly earnings data on Thursday, May, 14th. The company reported ($0.27) EPS for the quarter. Read the conference call transcript. How do I buy shares of Biosig Technologies? Shares of STEX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/14/2026Today6/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (7m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 STEX's financial health is in the Yellow zone, according to TradeSmith. STEX has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry Surgical, Medical, And Dental Instruments And Supplies Sub-IndustryMedical Equipment Current SymbolNASDAQ:STEX CIK1530766 WebN/A Phone(203) 409-5444FaxN/AEmployees50Year Founded2009Price Target and Rating Average Price Target for Biosig Technologies$8.00 High Price Target$8.00 Low Price Target$8.00 Potential Upside/Downside+714.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($9.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$462.77 million Net MarginsN/A Pretax Margin-312,430.81% Return on Equity-717.92% Return on Assets-336.75% Debt Debt-to-Equity RatioN/A Current Ratio13.90 Quick Ratio13.90 Sales & Book Value Annual Sales$40 thousand Price / Sales4,465.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.83 per share Price / Book1.18Miscellaneous Outstanding Shares181,800,000Free Float85,939,000Market Cap$178.60 million OptionableN/A Beta1.85 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:STEX) was last updated on 6/10/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIn 30 days, you'll wish you'd read this emailA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredThis IPO Could Make SpaceX Look Small (Read before June 16)A red-hot AI startup just filed to go public - already valued at nearly $1 trillion. Wall Street veteran Marc ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biosig Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biosig Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
